Trajan's global headquarters located in Ringwood, Melbourne, was visited by Michael Sukkar MP, Member for Deakin, Parliament of Australia on 4 February, 2015.
Mr Sukkar was pleased to tour a growing local advanced manufacturing facility, with Trajan exporting products used in scientific and medical analysis to customers in over 100 countries.
In the past, Trajan's SGE Analytical Science brand of chromatography consumables has been awarded an R&D100 Technology Innovation Award, Victorian Exporter of the Year and inducted into Victoria’s Manufacturing Hall of Fame.
Apart from the production of specialized components, Trajan also services the local Australian clinical and medical research sectors with a wide range of pathology consumables through its Grale HDS brand.
Mr Sukkar said it was a privilege to visit Trajan’s headquarters in Ringwood and hear the inspirational story behind this growing business.
“Stephen Tomisich and his team are at the forefront of analytical and medical science, developing and commercializing technologies that will make a real difference to the health and well-being of our nation,” he said.
“I look forward to visiting again soon and supporting this business as it continues to go from strength to strength.”
Chief Executive Officer of Trajan Stephen Tomisich said "It was a great opportunity to share our journey so far, and how we plan to contribute to a strong future of technology innovation and manufacturing in Australia."
Photo: Trajan's CEO Stephen Tomisich (right) explaining the critical features of an analytical syringe to Michael Sukkar MP (left).
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.